P
PepGen Inc. (PEPG)
NMS – Real vaqt narxi. Valyuta: USD
1.68
-0.02 (-1.18%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
1.68
-0.02 (-1.18%)
Yopilishda: May 12, 2026, 4:00 PM EDT
PepGen Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Amerika Qo'shma Shtatlarida og'ir neyromuskulyar va nevrologik kasalliklarni davolash uchun oligonukleotid terapiyalarini ishlab chiqadi. Kompaniya miyotonik distrofiya tip 1ni davolash uchun 2-bosqich klinik sinovdan o'tayotgan EDO peptid-konjugatsiyalangan PMO bo'lgan PGN-EDODM1ni ishlab chiqish bilan shug'ullanadi; va miyotonik distrofiya tip 1ni davolash uchun 2-bosqichda bo'lgan FREEDOM2-DM1ni ishlab chiqish bilan shug'ullanadi. Shuningdek, u ochiq etiketli kengaytirilgan tadqiqot FREEDOM-OLEda ishtirok etadi. Kompaniya 2018 yilda tashkil etilgan va Boston, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs & Quality |
| Dr. James G. McArthur Ph.D. | President, CEO, Treasurer, Secretary & Director |
| Dr. Kasra Kasraian Ph.D. | Chief Technical Officer |
| Dr. Paul D. Streck M.B.A., M.D. | Executive VP and Head of Research & Development |
| Mr. Gregory Song | Executive Director & Head of Biometrics |
| Mr. Joseph D. Vittiglio Esq., J.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 8-K | pepg-20260512.htm |
| 2026-04-28 | DEFA14A | defa14a_04.28.2026.htm |
| 2026-04-28 | DEF 14A | pepg-20260428.htm |
| 2026-03-30 | 8-K | pepg-20260330.htm |
| 2026-03-04 | S-8 | pepg-20260304.htm |
| 2026-03-04 | 8-K | pepg-20260304.htm |
| 2025-12-08 | 8-K | pepg-20251208.htm |
| 2025-11-12 | 10-Q | pepg-20250930.htm |
| 2025-11-07 | 8-K | pepg-20251104.htm |
| 2025-10-01 | 8-K | pepg-20251001.htm |
| Chief Business & Legal Officer and Secretary |
| Mr. Noel P. Donnelly M.B.A. | Chief Financial Officer |
| Ms. Emiko Bryant | Senior Vice President of HR & Administration |
| Ms. Melissa Michaels | Executive Director & Head of Regulatory Affairs CMC |
| Ms. Pallavi Lonkar Ph.D. | Vice President & Head of Preclinical |